Shut Down

Tute Genomics Stock

Cloud-based genomics testing platform

Sign up today and learn more about Tute Genomics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Tute Genomics Stock

Tute Genomics is a cloud-based clinical genome interpretation platform that enables researchers and clinicians to utilize human genome data for scientific discovery and individualized treatment. The cost of whole genome sequencing is dropping rapidly and we are at the beginning of a genomics revolution. As genome sequencing becomes standard practice for both clinicians and researchers, the need for user-friendly, accurate and rapid data analysis becomes the major barrier to making important diagnoses and discoveries. To meet this demand, Tute Genomics has developed the most advanced analytical methods for genome analysis by incorporating proprietary machine-learning algorithms into a cloud based application that allows researchers to analyze & interpret entire human genomes and discover genes and biomarkers at an unprecedented rate. Tute is opening a new door by helping researchers and clinicians interpret genetic variants and find disease-related genes. Tute is a robust successor to ANNOVAR, the most widely used genome annotation & interpretation technology with over 800 scientific publications.

Funding History

January 2013$0
January 2014$1.5M
December 2014$2.3M
June 2015$3.9M



Reid Robison

Sr Front End Engineer

Tony Lefler

VP, Business Development

S. George Simon

Director, Operations

Mary Brown


Kai Wang

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: